Microbial Fermentation Market Size to Surpass USD 54.62 BN by 2032

The global microbial fermentation technology market size is expected to surpass around USD 54.62 billion by 2032 and is poised to grow at a CAGR of 5.84% from 2023 to 2032.

The global microbial fermentation technology market size was estimated at USD 30.96 billion in 2022. Globally, the microbial fermentation technology market is increasing, attributed to the factors like increase in research and development overall, increase in the chronic and infectious diseases demanding to produce novel therapeutics and increase in emerging advancements in microbial fermentation.

Ask here for Sample Pages@ https://www.visionresearchreports.com/report/sample/39494

Key Insights

• The antibiotics segment captured the largest market share of 32.24% in 2022.
• The CMOs and CDMOs segment dominated the market and accounted for the highest share of 42.25% in 2022.
• Asia Pacific dominated the market and accounted for the highest revenue share of 45.93% in 2022.

Drivers

Increasing demand for microbial contract servicing

Fermentation is an important but difficult step in both drug and food production as the companies look to produce the core ingredients that produces their eventual end products. This procedure is easy to be done in- house but the expertise contract fermentation services provide can improve the affordability, quality, scalability and speed and scalability of the program. Additionally, there are various pharmaceutical companies that provide the microbial contract service. For instance, the AbbVie company provides the fermentation overall contract that includes microbial fermentation, yeast fermentation, strain development, fermentation process validation. As there is a continuous commercial demand from the companies in scaling up their fermentation process, the increase in the microbial contract servicing will tend to expand.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/39494

You can further customize the report@ https://www.visionresearchreports.com/report/customization/39494

Scope of this report

Market Restraints

Stringent regulations by the regulatory government bodies

The microbial fermentation technology market has various benefits in pharmaceutical as well as food industry and these services are also offered by CRO’s and CDMO’s. Additionally, the government also has focus on the production of these biopharmaceutical contents and fermented food by microbial fermentation technology, but it comes with stringent regulations as this technology employs the use of microorganisms. For instance, there are FDA-regulations on wines, beers, plant proteins. The manufacturers or the company owner must show the records that their food produced is gluten-free before hydrolysis or fermentation occur. These regulations are made for the consumer confidence, that includes the clarity, consistency, harmonization and ensuring safe production with better storage and transport. Thus, these regulations although safe for the consumers can act as a hindrance factor for the growth of the market.

Opportunity

Stipulation in the innovation of drugs.

Even before the pandemic, drug, small molecule, and biosimilar innovation was a significant trend. Even so, there has been a significant increase in research and development since the pandemic, particularly around vaccine production. Additionally, antibiotic resistance is growing every day. For example, the Centres for Disease Control and Prevention reports that every year in the United States, more than 2.8 million infections are caused by antimicrobial resistance. As a result, there is more room for ongoing research and development as new novel therapeutics are being developed. Therefore, increased drug innovation presents a favourable opportunity for the growth of the global market for microbial fermentation.

By Application

Based on the application segment, the Microbial Fermentation market is fragmented antibiotics, vaccines, and others. The vaccines segment is expected to grow in the forecasted period. The growth of the vaccine is driven majorly after the pandemic, as the vaccines have been in the market for the long time although their mass-market commercialization was enabled due to pandemic. Additionally, the usage of the vaccines in curing and preventing infectious diseases like pneumonia, influenza, rotavirus, bacterial infections like staphylococcus, streptococcus have boosted the vaccine market globally. Furthermore, the increasing awareness of research and development, expansion of healthcare infrastructure, government support and focus are the other factors for the expansion of the market.

Moreover, the microbial fermentation technology is used in the production of the vaccine in bulk. According to Barry Buckland, vice president of Merck Research labs, the yeast cells are allowed to multiply in a fermenter and make a virus like particle that looks like a real virus with nothing inside, after fermentation these yeast cells are collected and ruptured and used in making vaccine. Additionally, microbial fermentation takes less down time with higher productivity, which is advantageous in producing vaccine because it requires quick and rapid results. Also, the microbial fermentation being an old method, employs less expensive media, has lower costs and minimal issues in regards with contamination. Additionally, many vaccine producing companies are upgrading and improving their biotech sites for better yield of vaccine production. For example, Wacker company that is Munich based states that it is making improvements to its Amsterdam-based facilities for producing live microbial products and vaccines. The projects involve building a new 1,500-liter fermentation line as well as brand-new cleanroom structures for the existing 270-liter fermentation line. According to the company, the investment price is in the double digit million euro. As, a result, the expansion of the vaccine production will simultaneously drive the growth of microbial fermentation technology market.

By End-user

Based on the end-user segment, the Microbial Fermentation market is fragmented into pharmaceuticals, biopharmaceuticals, and food industry. The food industry segment is expected to grow in the forecasted period. The prime increase in the demand for the food is due to the increase in the population. Additionally, the fermented food is trending currently due to the numerous advantages that it offers. The preference for healthy food, increased awareness regarding the health benefits of fermented food and beverages, increased popularity for probiotics are few factors that increase the growth of the market. Also, for consistency and commercial viability, modern fermentations rely on defined starter cultures with desirable properties and the complex interactions between bacterial species and the food matrix the food industries are fermenting can be understood through microbial fermentation.

Furthermore, the microbial fermentation in food leads to major advantages like it changes the biochemical and nutritional quality of the ingredients Additionally, the fermented food also has complex ecosystem consisting of enzymes from raw ingredients that interact with the fermenting metabolic activities. Apart from that, the fermentation not only increases the microbiological safety and the shelf life making the food more digestible and less toxic. Moreover, the food fermentation and its unique food metabolic activities are used in variety of foods like meat, milk, cereals, and vegetables. Therefore, the food industry is a wide industry and the fermented food is trending currently, expanding the growth of the microbial fermentation technology market.

Regional landscape

By regional, the Asia-Pacific is expected to dominate the market in the forecasted period. The growth is fuelled by increased research and development in the area, high levels of drug, vaccine, and pharmaceutical processing, as well as funding initiatives and government focus. The second-largest region in the world is now Asia-Pacific, owing to the region’s growing number of pharmaceutical companies and its emphasis on production. For instance, China will build several bioprocessing facilities to meet domestic demand. According to a research study, China will have the largest pharmaceutical industry in the world in less than 10 years because it currently accounts for 12% of the global pharmaceutical market.

Furthermore, the number of CDMOs AND CROs has sharply increased. The stats show that 54% of the global pharmaceutical CRO market was made up of CROs in China. Additionally, India has a rich tradition of food preservation through fermentation, with microbial fermentation being the most widely used method. Therefore, Asia-pacific along with the increasing pharma, also have the traditional ways of microbial fermentation expanding the growth of the market.

Related Reports

• Biotechnology Market - The global biotechnology market size is expected to be worth around US$ 3.44 trillion by 2030 from valued at US$ 852.88 billion in 2020 and is anticipated to grow at a CAGR of 17.83% during forecast period 2021 to 2030.
• Clinical Trials Market - The global clinical trials market size is anticipated to reach around US$ 95 billion by 2030 from US$ 48 billion in 2020, expanding growth at a CAGR of 7.07% during forecast period 2022 to 2030.
• Cell and Gene Therapy Market - The cell and gene therapy market size was valued at USD 5.9 billion in 2021 and is expected to hit around USD 42.56 billion by 2030, growing at a CAGR of 39.42 % during the forecast period 2022 to 2030.

Recent developments

1. September 2021, BIOVECTRA and ABEC formed a partnership, with ABEC providing CSR single-use microbial fermentation technology to expand BIOVECTRA’s manufacturing capabilities.
2. November 2021, Lonza planned to spend more than $1 billion to increase its ability to produce microorganisms in Visp, Switzerland.
3. March 2022, A microbial ingredients fermentation facility with a 53,800-square-foot footprint will be built by Bio-Cat Microbial with an investment of USD 35 million. The undertaking, which should be finished by May 2023, will increase the company’s production capacity by 40%.
4. September 2022, Cyclone Engineering, Genomatica, and Cargill collaborated on a project to expand bioreactor fermentation operations.

Key players:

• Biocon Ltd.
• Danone UK
• Lonza
• Bio Vectra Inc.
• BIOZEEN
• Novozymes A/S
• Koninklijke DSM NV
• TerraVia Holdings, Inc.
• F. Hoffmann-La Roche AG
• WuXi Biologics

Segments covered in the report:

By Application

• Antibiotics
• Probiotics Supplements
• Monoclonal Antibodies
• Recombinant Proteins
• Biosimilars
• Vaccines
• Enzymes
• Small Molecules
• Others

By End-User

• Pharmaceuticals
• Biopharmaceuticals
• Food Industry
• Others

By Region

• North America

• US
• Canada

• Europe

• UK
• Germany
• France
• Spain
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• Rest of Asia Pacific

• LAMEA

• Brazil
• GCC

Rest of LAMEA

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/39494

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/